A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
Start Date
6/2/2026
Completion Date
1/7/2028
Summary
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
Detailed Description
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD). Participants will continue their standard background COPD therapy. Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.
Eligibility Criteria
Age Range: 40 years to 80 years
Interventions
WIN378
Placebo
Conditions
Locations
WB Contracted Clinical Research Site
Miami Lakes, Florida 33014
United States
WB Contracted Clinical Research Site
North Dartmouth, Massachusetts 02747
United States
WB Contracted Clinical Research Site
Charlotte, North Carolina 28277
United States
WB Contracted Clinical Research Site
McKinney, Texas 75069
United States